Coronavirus: Commission approves contract with CureVac to ensure access to a potential vaccine
The European Commission yesterday approved a fifth contract with the European pharmaceutical company CureVac, which provides for the initial purchase of 225 million doses on behalf of all EU Member States, plus an option to request up to a further 180 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19.
Yesterday's contract with CureVac enlarges the already broad portfolio of vaccines to be produced in Europe, including the contracts signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV and BioNtech-Pfizer, and the successful exploratory talks with Moderna. This diversified vaccines portfolio will ensure Europe is well prepared for vaccination, once the vaccines have been proven to be safe and effective. Member States can also decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.
President of the European Commission, Ursula von der Leyen, yesterday said:
“A few days after our contract with BioNTech and Pfizer, I am delighted to announce a new agreement with a promising European company. The Commission has secured to date at least 1.2 billion doses and fulfils its commitment to ensuring equitable access to safe, effective and affordable vaccines not only for EU citizens but also for the world's poorest and most vulnerable people. Most of these vaccine candidates are in an advanced phase of clinical trials, hopefully authorisation will confirm these positive results, after which they will be quickly deployed and help us in overcoming the pandemic.”
Stella Kyriakides, Commissioner for Health and Food Safety, yesterday said:
“With growing numbers of COVID patients across the EU, a safe and effective vaccine is more crucial than ever in putting behind us the pandemic. With this fifth vaccine advance purchase agreement, we are further expanding the possibilities that EU citizens and our economies can soon safely return to normality. It is yet another milestone in our EU Vaccines Strategy, and evidence of the benefits of working together in a genuine European Health Union.”
CureVac, a European company based in Germany, signed a €75 million loan agreement with the European Investment Bank on 6 July for the development and large-scale production of vaccines, including CureVac's vaccine candidate against COVID-19. CureVac is pioneering the development of a completely new class of vaccines based on messenger RNA (mRNA), transported into cells by lipid nanoparticles. The vaccine platform has been developed over the last decade. The basic principle is the use of this molecule as a data carrier for information, with the help of which the body itself can produce its own active substances to combat various diseases.
The Commission has taken a decision to support this vaccine based on a sound scientific assessment, the technology used, the company's experience in vaccine development and its production capacity to supply the whole of the EU.
Latest News from
Ukraine: EU report notes continued implementation of the reform agenda though challenges remain02/12/2020 09:25:00
Ahead of the informal meeting of the members of the EU-Ukraine Association Council on 8 December, the European Union yesterday published its annual Association Implementation Report on Ukraine.
EIB Group cooperates with Hypo Vorarlberg to support climate action investments02/12/2020 08:20:00
The EIB Group, consisting of the European Investment Bank (EIB) and the European Investment Fund (EIF), has provided a mezzanine guarantee on a €330 million portfolio of mainly Austrian loans to SMEs and mid-caps, originated by Hypo Vorarlberg Bank AG.
Debt relief efforts for African countries: Council approves conclusions01/12/2020 16:33:00
The EU is committed to furthering international debt relief efforts for African countries.
Civil protection: Council agrees its negotiating mandate to strengthen disaster prevention, preparedness and response01/12/2020 15:25:00
EU ambassadors yesterday agreed a negotiating mandate on a proposal to strengthen the EU civil protection mechanism.
Team Europe COVID-19 response: EU announces €20 million to support health systems in ASEAN01/12/2020 14:33:00
As part of Team Europe's global response to the coronavirus pandemic, the European Union announced today a new €20 million programme to support the preparedness and response capacities of our partners in the Association of Southeast Asian Nations (ASEAN).
Coming up: migration, digital working, water01/12/2020 13:25:00
MEPs will discuss the right to disconnect digitally from work, EU asylum rules and legislation on water in the coming week.
EU greenhouse gas emissions fell in 2019 to the lowest level in three decades01/12/2020 12:38:00
The Commission yesterday adopted its annual EU Climate Action Progress Report, covering the EU's progress in cutting greenhouse gas emissions in 2019.
First Schengen Forum: Towards a stronger and more resilient Schengen area01/12/2020 10:33:00
The first ever Schengen Forum, convened yesterday by the Commission, allowed for constructive exchanges towards building a stronger and more resilient Schengen area.
Parliament wants to grant EU consumers a “right to repair”27/11/2020 10:38:00
Parliament wants to boost sustainability by promoting reuse and repairs and by tackling practices that shorten the lifespan of products.